Advertisement

Keine Nitrattoleranz nach kontinuierlicher oraler Gabe von PETN

  • Senta Müller
  • J. Müllenheim
  • Ute Laber
  • W. Meyer
  • B. Fink
  • V. Thämer
  • G. Kojda
Chapter
  • 11 Downloads

Zusammenfassung

Wie eine Studie am Cholesterol-gefütterten Kaninchen gezeigt hat, führt die Behandlung mit einer Einzeldosis von 6 mg PETN/kg KG/Tag bei bereits etablierter Atherosklerose zu:
  • einer signifikanten Verringerung der Fläche der atherosklerotischen Läsionen in der thorakalen Aorta

  • einer Verhinderung der Progression der endothelialen Dysfunktion (keine weitere Einschränkung der endothelabhängigen Relaxation trotz drastischer Hypercholesterolämie)

  • einer signifikanten Verringerung der Oxidation von LDL in vivo.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ahlner J, Andersson RGG, Torfgârd K, Axelsson KL (1991) Organic nitrate esters: Clinical use and mechanisms of actions. Pharmacol Rev 43: 351–423PubMedGoogle Scholar
  2. 2.
    Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG (2000) Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 105: 1631–1639PubMedCrossRefGoogle Scholar
  3. 3.
    Gruppo Italiano per to Studio della Sopravvivenza nell’Infarto Miocardico (1994) GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate single and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343: 1115–1122Google Scholar
  4. 4.
    Hacker A, Noack E, Kojda G (2000) Continuous treatment with pentaerythritol tetranitrate prevents the increase of LDL-oxidation in established atherosclerosis. In: Navaro-Lopez F (ed) XXI Congress of the European Society of Cardiology. Monduzzi Editore, Italy, p 251–257Google Scholar
  5. 5.
    ISIS-4 Collaborative Group (1995) ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 345: 669–685Google Scholar
  6. 6.
    Kojda G, Hacker A, Noack E (1998) Effects of non-intermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and vascular superoxide production. Eur J Pharmacol 355: 23–31PubMedCrossRefGoogle Scholar
  7. 7.
    Kojda G, Harrison DG (1999) Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 43: 562–571PubMedCrossRefGoogle Scholar
  8. 8.
    Kojda G, Stein D, Kottenberg E, Schnaith EM, Noack E (1995) In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol 25: 763–773PubMedCrossRefGoogle Scholar
  9. 9.
    Miles AM, Bohle DS, Glassbrenner PA, Hansert B, Wink DA, Grisham MB (1996) Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J Biol Chem 271: 40–47PubMedCrossRefGoogle Scholar
  10. 10.
    Münzel T, Harrison DG (1997) Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance. J Mol Med 75: 891–900PubMedCrossRefGoogle Scholar
  11. 11.
    Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG (1995) Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187–194Google Scholar
  12. 12.
    Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG (1995) Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187–194Google Scholar
  13. 13.
    Parker JD, Parker JO (1998) Nitrate therapy for stable angina pectoris. N Engl J Med 338: 520–531PubMedCrossRefGoogle Scholar
  14. 14.
    Weber W, Michaelis K, Luckow V, Kuntze U, Stalleicken D (1995) Pharmacokinetics and bioavailability of pentaerythrityl tetranitrate and two of its metabolites. Arzneim Forsch 45: 781–784Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Senta Müller
  • J. Müllenheim
  • Ute Laber
  • W. Meyer
  • B. Fink
  • V. Thämer
  • G. Kojda

There are no affiliations available

Personalised recommendations